A Study of TAK-861 in Participants With Narcolepsy Type 1
Status:
Not yet recruiting
Trial end date:
2024-05-29
Target enrollment:
Participant gender:
Summary
The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including
excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in
the study across North America, Europe and Asia Pacific.
The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this
treatment period the participant will have the option to participate in a separate, long-
term extension study during which all participants will be treated with TAK-861.